VP of Clinical Development

$335k - $360k

Location
San Diego
Workplace
On-site
Employment
Full-time

About this role

Company Overview

Equillium, Inc. (Nasdaq: EQ) is a biotechnology innovator with a mission to develop highly impactful therapies for serious autoimmune and inflammatory disorders. The company is building a focused, wholly owned pipeline of targeted therapeutics designed to address tissue inflammation and restore immune and barrier homeostasis. Equillium’s lead program, EQ504, is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multimodal, non-immunosuppressive mechanism of action. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted, delayed-release drug product.


Position Overview

The Vice President, Clinical Development, I&I will provide medical and strategic leadership for Equillium’s
clinical portfolio, with primary responsibility for the clinical development of EQ504 in ulcerative colitis and pulmonary indications, as well as secondary support for EQ302 in celiac disease.


Essential Duties and Responsibilities

  • Lead the integrated clinical development strategy and clinical development plan for EQ504 in ulcerative colitis, including indication strategy, target product profile, evidence-generation plan, decision criteria, timelines and budgets.
  • Provide medical leadership for the ongoing EQ504 Phase 1 proof-of-mechanism study, including protocol execution, dose and regimen evaluation, safety monitoring, data review, interpretation and communication of results.
  • Lead the planning and design of a Phase 2 study in patients with ulcerative colitis to follow the Phase 1 study, including development of the protocol and statistical framework, patient population and eligibility criteria, dose and regimen selection, endpoints, biomarkers, site and country strategy, operational feasibility, budget, timelines and regulatory alignment.
  • Provide clinical development input for EQ302 in celiac disease.
  • Lead development of clinical protocols, investigator brochures, clinical study reports, clinical sections of regulatory submissions and briefing materials for health authority interactions.
  • Provide medical oversight of clinical trials, including eligibility and enrollment issues, protocol deviations, emerging efficacy and biomarker data, and aggregate safety assessment in partnership with Pharmacovigilance.
  • Guide clinical pharmacology, biomarker and translational strategies that establish proof of mechanism, support Phase 2 dose selection and strengthen the differentiation of EQ504; advise on EQ302 selectively as needed.
  • Contribute to portfolio, business development, financing and investor activities by clearly communicating program strategy, clinical rationale, development risks and value-creating milestones.

Key Measures of Success

  • High-quality execution and interpretation of the EQ504 Phase 1 program and a Phase 2 ulcerative colitis study that is designed, operationally feasible and ready to initiate following supportive Phase 1 results.
  • Focused, fit-for-purpose clinical development support for EQ504 pulmonary indications and EQ302 for celiac disease.
  • Timely delivery of clinical and regulatory milestones with disciplined risk management and transparent communication.
  • Strong engagement with leading gastroenterology investigators and advisors, and a compelling external scientific profile for the portfolio.
  • Effective cross-functional leadership that aligns strategy, operations and decision-making.


Education and Experience

  • M.D. or Ph.D. required.
  • Board certification or advanced clinical training in gastroenterology is strongly preferred.
  • Typically, 12 or more years of relevant biopharmaceutical clinical development experience, including meaningful leadership responsibility for I&I programs.
  • Demonstrated expertise in inflammatory bowel disease, particularly ulcerative colitis; experience in celiac disease, immune-mediated gastrointestinal disorders, and/or pulmonary diseases is highly desirable.


Skills and Leadership Attributes

  • Decisive, pragmatic, and comfortable operating hands-on in a dynamic fast-moving organization.
  • Strategic, collaborative, low-ego leader who creates clarity and accountability.
  • Ability to travel domestically and internationally up to approximately 25%.


Equal Opportunity

Equillium is an equal opportunity employer.


This JD has been shortened. Interviewing candidates will be provided the longer version upon advancing into the interviewing process.


Apply to Equillium, Inc.

Clera fills in Equillium, Inc.'s application for you.

How it works

Open the role in Clera

Sign in, and this role opens on your Clera job board, ready to apply.

Clera fills in the application

Clera fills the form from your profile and resume, and asks what's missing.

Track it in Clera

Each application you send shows up in your Clera tracker, sorted by stage.

Want Clera to find roles for you?

Ask your AI about this role

It knows you. Clera gives it the role.

Does this role fit my profile?

First time? Connect Clera once, about a minute.
One click above pre-fills the connector. Or by hand: Settings > Connectors > Add custom connector, paste https://mcp.getclera.com. Either way, sign in with the account you use on Clera and approve the consent screen.
https://mcp.getclera.com

Sign in with your Clera account. MCP docs

About Equillium, Inc.

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need.

Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders – this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.

Team size
11-50 employees people
Founded
2017
Industry
Biotechnology Research
Workplace
On-site
Locations
San Diego, California, United States